WeSearch

New drug could fight ‘Ozempic butt’ — and some other unwelcome side effects of GLP-1 drugs

·5 min read · 0 reactions · 0 comments · 31 views
#drug#could#fight#ozempic#butt
New drug could fight ‘Ozempic butt’ — and some other unwelcome side effects of GLP-1 drugs
TL;DR · WeSearch summary

Health New drug could fight ‘Ozempic butt’ — and some other unwelcome side effects of GLP-1 drugs By Reda Wigle Published June 11, 2026, 10:14 a.m. ET See more of our coverage in your search results. Add The New York Post on Google You may yet be able to lean out without losing out, as a new drug could save GLP-1 users from the flat fate of “Ozempic butt.” A symptom of rapid weight loss, Ozempic butt is characterized by a sudden loss of volume and muscle in key areas, leaving users looking and feeling deflated.

Key facts
About this source

New York Post files mainly under news. We currently carry 10,371 of its stories.

Original article
New York Post
Read full at New York Post →
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →

Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.

Record

Original publisherNew York Post
Canonical URLhttps://nypost.com/2026/06/11/health/new-drug-could-fight-ozempic-butt-and-other-unwelcome-side-effects/
Publication timeThu, 11 Jun 2026 10:14:17 -0400
Retrieval time2026-06-11T14:28:28.756Z
Last seen2026-06-11T14:28:28.756Z
Headline sourcePublisher (no WeSearch rewrite)
Excerpt sourcepublisher body
Excerpt methodFirst ~120 words (~800 chars) of extracted publisher body, fair-use limited.
SummaryWeSearch · cerebras-chat (WeSearch summarizer)
Summary source textcontentText
Citation coverageSummary is a WeSearch-generated derivative; primary citation is the original publisher URL.
ClusterCS3af0mq8frA
Cluster logicGrouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison.
Ranking reasonStory pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking.
Publisher visitYes — open original
Substitutes article?No — link-out required for full text

Rights status (four layers)

Publisher-declared
No publisher-confirmed rights record for this source yet.
Machine-readable
No source-specific machine-readable restriction detected beyond the public feed.
WeSearch interpretation
WeSearch declared handling (basis: Derived from the published RSS/Atom feed). This is WeSearch policy, not a legal grant on the publisher's behalf.
Unknown
Retrieval and training permissions are not asserted unless the publisher confirms them.

WeSearch handling by dimension

Indexing May the item be indexed (stored, ranked, made findable)? Allowed
Snippet May a short excerpt of the publisher's text be shown? Allowed
AI summary May WeSearch generate its own short summary of the article? Limited
Retrieval / RAG May the content be exposed for third-party retrieval-augmented generation? Not asserted
Model training May the content be used to train AI models? Not asserted
Commercial reuse May the content be reused commercially? Not permitted

Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.

Opening excerpt (first ~120 words) tap to expand

Health New drug could fight ‘Ozempic butt’ — and some other unwelcome side effects of GLP-1 drugs By Reda Wigle Published June 11, 2026, 10:14 a.m. ET See more of our coverage in your search results. Add The New York Post on Google You may yet be able to lean out without losing out, as a new drug could save GLP-1 users from the flat fate of “Ozempic butt.” A symptom of rapid weight loss, Ozempic butt is characterized by a sudden loss of volume and muscle in key areas, leaving users looking and feeling deflated. And Americans are losing weight faster than ever thanks to drugs like Wegovy and Zepbound, with roughly one in eight US adults now turning to GLP-1s to slim down. A symptom of rapid weight loss, Ozempic butt, like Ozempic face, is characterized by a sudden loss of volume.

Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.

Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from New York Post